U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284186) titled 'First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors' on Nov. 20.
Brief Summary: A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies.
The study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which...